135 related articles for article (PubMed ID: 31468568)
1. Repeated ketamine injections in synergy with antidepressants for treating refractory depression: A case showing 6-month improvement.
Wang M; Xiong Z; Su B; Wang L; Li Z; Yang Y; Fang J; Li Z
J Clin Pharm Ther; 2020 Feb; 45(1):199-203. PubMed ID: 31468568
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study.
Vidal S; Gex-Fabry M; Bancila V; Michalopoulos G; Warrot D; Jermann F; Dayer A; Sterpenich V; Schwartz S; Vutskits L; Khan N; Aubry JM; Kosel M
J Clin Psychopharmacol; 2018 Dec; 38(6):590-597. PubMed ID: 30346333
[TBL] [Abstract][Full Text] [Related]
3. Intravenous ketamine infusion for a patient with treatment-resistant major depression: a 10-month follow-up.
Kwon JH; Sim WS; Hong JP; Song IS; Lee JY
J Clin Pharm Ther; 2018 Aug; 43(4):581-583. PubMed ID: 29372569
[TBL] [Abstract][Full Text] [Related]
4. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression.
Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y
J Psychopharmacol; 2018 Oct; 32(10):1118-1126. PubMed ID: 30260273
[TBL] [Abstract][Full Text] [Related]
5. Continuation phase intravenous ketamine in adults with treatment-resistant depression.
Vande Voort JL; Morgan RJ; Kung S; Rasmussen KG; Rico J; Palmer BA; Schak KM; Tye SJ; Ritter MJ; Frye MA; Bobo WV
J Affect Disord; 2016 Dec; 206():300-304. PubMed ID: 27656788
[TBL] [Abstract][Full Text] [Related]
6. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression.
Shiroma PR; Johns B; Kuskowski M; Wels J; Thuras P; Albott CS; Lim KO
J Affect Disord; 2014 Feb; 155():123-9. PubMed ID: 24268616
[TBL] [Abstract][Full Text] [Related]
7. A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression.
Szymkowicz SM; Finnegan N; Dale RM
J Affect Disord; 2013 May; 147(1-3):416-20. PubMed ID: 23182590
[TBL] [Abstract][Full Text] [Related]
8. Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation.
Cusin C; Ionescu DF; Pavone KJ; Akeju O; Cassano P; Taylor N; Eikermann M; Durham K; Swee MB; Chang T; Dording C; Soskin D; Kelley J; Mischoulon D; Brown EN; Fava M
Aust N Z J Psychiatry; 2017 Jan; 51(1):55-64. PubMed ID: 26893373
[TBL] [Abstract][Full Text] [Related]
9. The Concurrent Treatment With Intravenous Ketamine and an Irreversible Monoamine Oxidase Inhibitor for Treatment-Resistant Depression Without Hypertensive Crises.
Wang JCC; Swainson J
J Clin Psychopharmacol; 2020; 40(5):515-517. PubMed ID: 32740556
[No Abstract] [Full Text] [Related]
10. Intravenous arketamine for treatment-resistant depression: open-label pilot study.
Leal GC; Bandeira ID; Correia-Melo FS; Telles M; Mello RP; Vieira F; Lima CS; Jesus-Nunes AP; Guerreiro-Costa LNF; Marback RF; Caliman-Fontes AT; Marques BLS; Bezerra MLO; Dias-Neto AL; Silva SS; Sampaio AS; Sanacora G; Turecki G; Loo C; Lacerda ALT; Quarantini LC
Eur Arch Psychiatry Clin Neurosci; 2021 Apr; 271(3):577-582. PubMed ID: 32078034
[TBL] [Abstract][Full Text] [Related]
11. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic.
Diamond PR; Farmery AD; Atkinson S; Haldar J; Williams N; Cowen PJ; Geddes JR; McShane R
J Psychopharmacol; 2014 Jun; 28(6):536-44. PubMed ID: 24699062
[TBL] [Abstract][Full Text] [Related]
12. Ketamine and Monoamine Oxidase Inhibitor Combination: Utility, Safety, Efficacy?
Bottemanne H; Bonnard E; Claret A; Petit AC; Gaillard R; Fossati P
J Clin Psychopharmacol; 2020; 40(6):636-638. PubMed ID: 33009225
[No Abstract] [Full Text] [Related]
13. Effect of Ketamine on Rumination in Treatment-Resistant Depressive Patients.
Vidal S; Jermann F; Aubry JM; Richard-Lepouriel H; Kosel M
J Clin Psychopharmacol; 2020; 40(6):607-610. PubMed ID: 33044358
[TBL] [Abstract][Full Text] [Related]
14. Esketamine for treatment-resistant depression.
Drug Ther Bull; 2020 Dec; 58(12):183-188. PubMed ID: 33243929
[No Abstract] [Full Text] [Related]
15. Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study.
Ionescu DF; Swee MB; Pavone KJ; Taylor N; Akeju O; Baer L; Nyer M; Cassano P; Mischoulon D; Alpert JE; Brown EN; Nock MK; Fava M; Cusin C
J Clin Psychiatry; 2016 Jun; 77(6):e719-25. PubMed ID: 27232360
[TBL] [Abstract][Full Text] [Related]
16. Esketamine nasal spray (Spravato) for treatment-resistant depression.
Med Lett Drugs Ther; 2019 Apr; 61(1569):54-57. PubMed ID: 31169797
[No Abstract] [Full Text] [Related]
17. Intravenous ketamine for treatment-resistant major depressive disorder.
Covvey JR; Crawford AN; Lowe DK
Ann Pharmacother; 2012 Jan; 46(1):117-23. PubMed ID: 22190250
[TBL] [Abstract][Full Text] [Related]
18. Ketamine for the treatment of depression.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2013 Jan; 51(1):11-4. PubMed ID: 23413455
[TBL] [Abstract][Full Text] [Related]
19. Rapid and sustained improvement in treatment-refractory depression through use of acute intravenous ketamine and concurrent transdermal selegiline: A case series.
Lu BY; Agapoff JR; Olson DJ; Williams SR; Roller A; Goebert D
J Affect Disord; 2020 Feb; 262():40-42. PubMed ID: 31706158
[TBL] [Abstract][Full Text] [Related]
20. Can Quetiapine Prolong the Antidepressant Effect of Ketamine?: A 5-Year Follow-up Study.
Amiaz R; Saporta R; Noy A; Berkenstadt H; Weiser M
J Clin Psychopharmacol; 2021 Nov-Dec 01; 41(6):673-675. PubMed ID: 34668877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
